Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
F 2.63 3.95% 0.10
GLYC closed up 3.95 percent on Wednesday, April 14, 2021, on 76 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical GLYC trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 3.95%
Wide Bands Range Expansion 3.95%
Below Lower BB Weakness 3.95%
Down 3 Days in a Row Weakness 3.95%
Older End-of-Day Signals for GLYC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 16 hours ago
Rose Above Lower Bollinger Band about 16 hours ago
Up 5% about 16 hours ago
Up 3% about 16 hours ago
Up 2% about 16 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GlycoMimetics, Inc. Description

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Industry Diseases Drug Discovery Chemotherapy Clinical Trial Acute Myeloid Leukemia Product Testing Sickle Cell Disease Pseudomonas Hematologic Cancers Nursing Research

Is GLYC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.1899
52 Week Low 2.37
Average Volume 921,049
200-Day Moving Average 3.61
50-Day Moving Average 3.38
20-Day Moving Average 3.05
10-Day Moving Average 2.94
Average True Range 0.22
ADX 21.79
+DI 17.53
-DI 31.60
Chandelier Exit (Long, 3 ATRs ) 2.95
Chandelier Exit (Short, 3 ATRs ) 3.10
Upper Bollinger Band 3.58
Lower Bollinger Band 2.53
Percent B (%b) 0.1
BandWidth 34.54
MACD Line -0.18
MACD Signal Line -0.14
MACD Histogram -0.0404
Fundamentals Value
Market Cap 125.79 Million
Num Shares 47.8 Million
EPS -1.28
Price-to-Earnings (P/E) Ratio -2.05
Price-to-Sales 16.22
Price-to-Book 1.26
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.92
Resistance 3 (R3) 2.91 2.81 2.87
Resistance 2 (R2) 2.81 2.74 2.81 2.85
Resistance 1 (R1) 2.72 2.69 2.77 2.73 2.84
Pivot Point 2.62 2.62 2.64 2.62 2.62
Support 1 (S1) 2.53 2.55 2.58 2.54 2.42
Support 2 (S2) 2.43 2.50 2.43 2.41
Support 3 (S3) 2.34 2.43 2.39
Support 4 (S4) 2.35